In today’s recent session, 1,430,130 shares of the Nabriva Therapeutics plc(NASDAQ:NBRV) have been traded, and its beta is 1.96. Most recently the company’s share price was $2.89, and it changed around -$0.14 or -0.04% from the last close, which brings the market valuation of the company to $60.5 Million. NBRV at last check was trading at a discount to its 52-week high of $16.2, offering almost -460.55% off that amount. The share price’s 52-week low was $2.31, which indicates that the recent value has risen by an impressive 20.07% since then. We note from Nabriva Therapeutics plc’s average daily trading volume that its 10-day average is 1.62 Million shares, with the 3-month average coming to 1Million.
Nabriva Therapeutics plc stock received a consensus recommendation rating of Overweight, based on a mean score of 2.7. If we narrow it down even further, the data shows that none out of 3 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 2 recommended NBRV as a Hold, whereas 1 deemed it a Buy, and no one rated it as Underweight. Nabriva Therapeutics plc is expected to report earnings per share of -$0.95 for the current quarter.
Nabriva Therapeutics plc (NASDAQ:NBRV): Trading Information Today
Although NBRV has been showing red trend so far today with a performance of -4.46% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of $3.28- on Thursday, Feb 18 increased the stock’s daily price by 11.28%. The company’s shares are currently up 0.2% year-to-date, but still down -0.0643 over the last five days. On the other hand, Nabriva Therapeutics plc (NASDAQ:NBRV) is -0.08% down in the 30-day period. We can see from the shorts that 728.64 Million shares have been sold at a short interest cover period of 728.64 day(s).
The consensus price target as assigned by Wall Street analysts is $9, which translates to bears needing to increase their stock price by 211.42% from its current value. Analyst projections state that NBRV is forecast to be at a low of $9 and a high of $9. In order for the stock price to hit the forecast high, the stock would need to surge +211.42% from its current level, while the stock would need to crash 211.42% from its current level to reach the projected low.
Nabriva Therapeutics plc (NBRV) projections and forecasts
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of $600Million in revenue for the current quarter. 1 analysts expect Nabriva Therapeutics plc to make $910Million in revenue for the quarter ending March 01, 2021. The company’s sales for the same quarter a year ago was $333Million. Analysts predict that the company’s current quarter sales will jump, forecast at 80.2%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 31.1%. Nabriva Therapeutics plc earnings are expected to increase by 50.6% in 2021, but the outlook is negative 0% per year for the next five years.
Nabriva Therapeutics plc (NASDAQ:NBRV)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 0.45% of Nabriva Therapeutics plc shares, and 20.72% of them are in the hands of institutional investors. The stock currently has a share float of 20.82%. Nabriva Therapeutics plc stock is held by 60 institutions, with FMR, LLC being the largest institutional investor. By Dec 30, 2020, it held 9.48% of the shares, which is about 1.43 Million shares worth $3.46 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Hudson Bay Capital Management LP, with 3.62% or 545.34 Thousand shares worth $2.91 Million as of Sep 29, 2020, holds the second largest percentage of outstanding shares.